Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.5 USD | +0.81% | +2.80% | -13.63% |
May. 10 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
May. 08 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.63% | 1.19B | |
+42.04% | 54.04B | |
+43.57% | 41.96B | |
-1.15% | 41.92B | |
-7.59% | 28.35B | |
+11.98% | 26.35B | |
-22.50% | 19B | |
+8.05% | 13B | |
+28.99% | 12.28B | |
+25.55% | 12.19B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Transcript : Mirum Pharmaceuticals, Inc. Presents at UBS Biopharma Conference 2023, Nov-08-2023 02